MX2018006347A - Proteinas de fusion fmdv y e2 y usos de ellos. - Google Patents

Proteinas de fusion fmdv y e2 y usos de ellos.

Info

Publication number
MX2018006347A
MX2018006347A MX2018006347A MX2018006347A MX2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A MX 2018006347 A MX2018006347 A MX 2018006347A
Authority
MX
Mexico
Prior art keywords
fmdv
antigens
vaccine
fusion proteins
encompasses
Prior art date
Application number
MX2018006347A
Other languages
English (en)
Inventor
Bomchil Natalia
Audonnet Jean-Christophe
Reynard Frederic
Sigoillot-Claude Cecile
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2018006347A publication Critical patent/MX2018006347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención abarca vacunas o composiciones FMDV. La vacuna composición puede ser una vacuna o composición que contiene antígenos FMDV. La invención también abarca vectores recombinantes que codifican y que expresan antígenos FMDV, epítopos o inmunógenos que se puede utilizar para proteger animales, en particular ovinos, bovinos, caprinos o porcinos, contra FMDV. La invención además abarca métodos para hacer o producir polipéptidos antigénicos o antígenos.
MX2018006347A 2015-11-23 2016-11-16 Proteinas de fusion fmdv y e2 y usos de ellos. MX2018006347A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562259043P 2015-11-23 2015-11-23
PCT/US2016/062367 WO2017091418A1 (en) 2015-11-23 2016-11-16 Fmdv and e2 fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2018006347A true MX2018006347A (es) 2019-02-20

Family

ID=57570585

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006347A MX2018006347A (es) 2015-11-23 2016-11-16 Proteinas de fusion fmdv y e2 y usos de ellos.

Country Status (20)

Country Link
US (2) US9913891B2 (es)
EP (2) EP3380119B1 (es)
JP (2) JP6797206B2 (es)
KR (1) KR102153303B1 (es)
CN (1) CN108367067B (es)
AR (1) AR106792A1 (es)
AU (1) AU2016361305B2 (es)
BR (1) BR112018010494A8 (es)
CA (1) CA3006078A1 (es)
DK (1) DK3380119T3 (es)
ES (1) ES2899230T3 (es)
HK (1) HK1258695A1 (es)
MA (3) MA43310A (es)
MX (1) MX2018006347A (es)
NZ (1) NZ743236A (es)
RU (1) RU2714428C2 (es)
TW (1) TWI744260B (es)
UY (1) UY36995A (es)
WO (1) WO2017091418A1 (es)
ZA (1) ZA201803390B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019179345A1 (en) * 2018-03-19 2019-09-26 Boehringer Ingelheim (China) Investment Co., Ltd. Recombinant virus capable of stably expressing target proteins
CN109187993B (zh) * 2018-09-13 2020-06-16 中国农业科学院兰州兽医研究所 一种口蹄疫A型病毒sIgA抗体ELISA检测试剂盒及其应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CN110028160B (zh) * 2019-01-24 2022-04-29 暨南大学 一种功能性微藻固定化材料的制备方法及其应用
CN114423779B (zh) * 2019-06-28 2024-07-02 株式会社准绳生命科学 口蹄疫病毒疫苗组合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
DE3730599A1 (de) 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU8444798A (en) 1997-06-30 1999-01-25 Centre National De La Recherche Scientifique Improved method for transferring nucleic acid into the striped muscle and combination therefor
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
GB9929151D0 (en) * 1999-12-09 2000-02-02 Univ Cambridge Tech Peptide and polypeptide display
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
SI1651265T1 (sl) 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi
CA2571560C (en) 2004-06-25 2016-04-12 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
BRPI0621513A2 (pt) * 2006-03-17 2011-12-13 Indian Immunologicals Ltd partìculas quiméricas do tipo timovìrus
CN101293098A (zh) * 2007-04-28 2008-10-29 北京迪威华宇生物技术有限公司 一种重组牛o型口蹄疫病毒融合蛋白疫苗
RU2555342C2 (ru) 2009-09-10 2015-07-10 Мериал Лимитед Новые вакцинные составы, включающие сапонинсодержащие адъюванты
AU2011224188B2 (en) * 2010-03-12 2015-01-22 Boehringer Ingelheim Animal Health USA Inc. Bluetongue virus recombinant vaccines and uses thereof
RU2467014C2 (ru) * 2010-12-06 2012-11-20 Учреждение Российской академии наук Центр "Боинженерия" РАН Полиэпитопный белок, нуклеотидная последовательность, кодирующая полиэпитопный белок, плазмида с последовательностью, кодирующей полиэпитопный белок, и препарат полиэпитопного белка для индукции иммунного ответа против вируса ящура
KR20150084993A (ko) * 2012-11-16 2015-07-22 유나이티드 바이오메디칼 인크. 구제역 (fmd)에 대한 합성 펩티드-기재 응급 백신
JP6173479B2 (ja) * 2012-12-05 2017-08-02 ザヴァックス ジェネティクス ワクチン カンパニー リミテッドＴｈｅｖａｘ Ｇｅｎｅｔｉｃｓ Ｖａｃｃｉｎｅ Ｃｏ．， Ｌｔｄ． 抗原特異的ｔ細胞反応を誘導するための免疫原エンハンサーとしての融合タンパク質
CN103305542B (zh) * 2013-06-25 2015-03-11 江苏省农业科学院 一种重组噬菌体双表达载体及应用
EP3906939A1 (en) * 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CN103933581A (zh) * 2014-05-04 2014-07-23 贵州大学 一种基于csf-fmd二联基因工程疫苗的制备方法
US10010605B2 (en) 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof

Also Published As

Publication number Publication date
CN108367067B (zh) 2022-05-03
KR102153303B1 (ko) 2020-09-09
BR112018010494A8 (pt) 2019-02-26
RU2714428C2 (ru) 2020-02-14
RU2018122755A3 (es) 2019-12-26
ES2899230T3 (es) 2022-03-10
WO2017091418A1 (en) 2017-06-01
AU2016361305B2 (en) 2020-02-06
RU2018122755A (ru) 2019-12-26
JP6797206B2 (ja) 2020-12-09
CN108367067A (zh) 2018-08-03
DK3380119T3 (da) 2021-11-15
BR112018010494A2 (pt) 2018-11-13
US10363300B2 (en) 2019-07-30
EP3380119A1 (en) 2018-10-03
MA42640A1 (fr) 2019-05-31
EP3539566A1 (en) 2019-09-18
AU2016361305A1 (en) 2018-06-28
JP2020203890A (ja) 2020-12-24
EP3380119B1 (en) 2021-08-25
HK1258695A1 (zh) 2019-11-15
NZ743236A (en) 2019-12-20
US9913891B2 (en) 2018-03-13
CA3006078A1 (en) 2017-06-01
US20170143819A1 (en) 2017-05-25
JP2019500409A (ja) 2019-01-10
TWI744260B (zh) 2021-11-01
AR106792A1 (es) 2018-02-21
ZA201803390B (en) 2019-03-27
MA43310A (fr) 2021-04-28
TW201726708A (zh) 2017-08-01
UY36995A (es) 2017-06-30
US20180169216A1 (en) 2018-06-21
MA49414A (fr) 2020-04-22
MA42640B1 (fr) 2021-06-30
KR20180084995A (ko) 2018-07-25

Similar Documents

Publication Publication Date Title
JO3600B1 (ar) لقاحات مؤتلفة ل fmdv و استخداماتها
MX2018006347A (es) Proteinas de fusion fmdv y e2 y usos de ellos.
JOP20170022B1 (ar) لقاحات التهاب العين الفيروسي المهجنة المنقولة بواسطة اف ام دي في و استخداماتها
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
PH12018501047A1 (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
MX2017000838A (es) Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas.
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
EA202090049A1 (ru) Поксвирусные векторы, кодирующие антигены вич, и способы их применения
MX2022003658A (es) Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
MX2017016273A (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante.
PH12019500851A1 (en) Tolerogenic dna vaccine
EA201990711A1 (ru) Новый ehv сайт инсерции orf70
MX363149B (es) Vacunas de nucleoproteina de la influenza.
MX353786B (es) Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas.
MX2019007924A (es) Vacunas contra la influenza.
MX2016017094A (es) Composicion inmunógena de clostridium difficile.
NZ734938A (en) Leptospira immunoprotective proteins and methods of identification and use thereof
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof
UY36328A (es) Vacunas de fmdv recombinante y usos de las mismas
MX2017015705A (es) Modulador de celulas t potencializado capaz de modular la respuesta inmune, especificamente diseñado para su uso terapeutico como adyuvante potencializador de vacunas virales.